{"organizations": [], "uuid": "6228e836ed8bdcfd32011d56c1a856c04c419b03", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-geneuro-receives-orphan-drug-desig/brief-geneuro-receives-orphan-drug-designation-from-the-us-fda-for-gnbac1-in-chronic-inflammatory-demyelinating-polyneuropathy-idUSASM000JMZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Geneuro Receives Orphan Drug Designation From The Us FDA For Gnbac1 In Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.33, "site_type": "news", "published": "2018-02-23T01:37:00.000+02:00", "replies_count": 0, "uuid": "6228e836ed8bdcfd32011d56c1a856c04c419b03"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-geneuro-receives-orphan-drug-desig/brief-geneuro-receives-orphan-drug-designation-from-the-us-fda-for-gnbac1-in-chronic-inflammatory-demyelinating-polyneuropathy-idUSASM000JMZ", "ord_in_thread": 0, "title": "BRIEF-Geneuro Receives Orphan Drug Designation From The Us FDA For Gnbac1 In Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "geneuro sa", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Geneuro Sa:\n* GENEURO RECEIVES ORPHAN DRUG DESIGNATION FROM THE US FDA FOR GNBAC1 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)\n* FORTHCOMING DISCUSSIONS EXPECTED WITH FDA FOR DESIGN OF A PROOF-OF-CONCEPT PHASE 2 CLINICAL STUDY Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-23T01:37:00.000+02:00", "crawled": "2018-02-23T15:46:57.007+02:00", "highlightTitle": ""}